english.prescrire.org > Prescrire International > N°181 - April 2017

n°181

April 2017

Issue Contents
Editorial

Free  No thank you

p.87

New Products


Delamanid (Deltyba°) and multidrug-resistant pulmonary tuberculosis

p.89-92
For selected patients, with cardiac monitoring

INN Common stem: -onidine

p.92

Nivolumab (Opdivo°) and metastatic or inoperable lung cancer

p.93-94
After chemotherapy: better than docetaxel

Adalimumab (Humira°) and hidradenitis suppurativa

p.94-96
Risk of infection outweights any benefit

Ciclosporin eye drops (Ikervis°) and dry eye syndrome

p.96-97
The risks of an immunosuppressant, but no efficacy

Adverse Effects


Drug-induced posterior reversible encephalopathy syndrome

p.98-101

Ispaghula: allergic reactions from dose preparation, too

p.101

Free  Unborn children still exposed to NSAIDs

p.102

Reviews


Fractures related to bone fragility: prevention

p.103-106
First-choice treatments

Digoxin

p.107
In heart failure with atrial fibrillation

Outlook


Free  Toward better patient care: drugs to avoid in 2017

p.108-111

Free  Notable changes in the 2017 update

p.110

Free  Drugs that should not be used: swifter action required to protect patients

p.111

Masthead


Free  Masthead

p.86

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe